Περίληψη:
Background: People who inject drugs (PWID) are frequently incarcerated, which is associated with multiple negative health outcomes. Aim: We aimed to estimate the associations between a history of incarceration and prevalence of HIV and HCV infection among PWID in Europe. Methods: Aggregate data from PWID recruited in drug services (excluding prison services) or elsewhere in the community were reported by 17 of 30 countries (16 per virus) collaborating in a European drug monitoring system (2006–2020; n=52,368 HIV+/-; n=47,268 HCV+/-). Country-specific odds ratios (OR) and prevalence ratios (PR) were calculated from country totals of HIV and HCV antibody status and self-reported life-time incarceration history, and pooled using meta-analyses. Country-specific and overall population attributable risk (PAR) were estimated using pooled PR. Results: Univariable HIV OR ranged between 0.73 and 6.37 (median: 2.1; pooled OR: 1.92; 95% CI: 1.52–2.42). Pooled PR was 1.66 (95% CI 1.38–1.98), giving a PAR of 25.8% (95% CI 16.7–34.0). Univariable anti-HCV OR ranged between 1.06 and 5.04 (median: 2.70; pooled OR: 2.51; 95% CI: 2.17–2.91). Pooled PR was 1.42 (95% CI: 1.28–1.58) and PAR 16.7% (95% CI: 11.8–21.7). Subgroup analyses showed differences in the OR for HCV by geographical region, with lower estimates in southern Europe. Conclusion: In univariable analysis, a history of incarceration was associated with positive HIV and HCV serostatus among PWID in Europe. Applying the precautionary principle would suggest finding alternatives to incarceration of PWID and strengthening health and social services in prison and after release (‘throughcare’). © 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
Συγγραφείς:
Wiessing, L.
Kalamara, E.
Stone, J.
Altan, P.
van Baelen, L.
Fotiou, A.
Garcia, D.
Goulao, J.
Guarita, B.
Hope, V.
Jauffret-Roustide, M.
Jurgelaitienė, L.
Kåberg, M.
Kamarulzaman, A.
Lemsalu, L.
Kivite-Urtane, A.
Kolarić, B.
Montanari, L.
Rosińska, M.
Sava, L.
Horváth, I.
Seyler, T.
Sypsa, V.
Tarján, A.
Yiasemi, I.
Zimmermann, R.
Ferri, M.
Dolan, K.
Uusküla, A.
Vickerman, P.
Λέξεις-κλειδιά:
drug use; Europe; hepatitis C; human; Human immunodeficiency virus infection; prevalence; substance abuse, Drug Users; Europe; Hepatitis C; HIV Infections; Humans; Prevalence; Substance Abuse, Intravenous
